CSPC Pharmaceutical Group’s Stock Price Dips to 4.72 HKD, Marks a 2.88% Decline

CSPC Pharmaceutical Group (1093)

4.72 HKD -0.14 (-2.88%) Volume: 214.63M

“CSPC Pharmaceutical Group’s stock price stands at 4.72 HKD, witnessing a dip of -2.88% this trading session with a trading volume of 214.63M shares, further consolidating its YTD performance at -34.99%.”

Latest developments on CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited has been making headlines recently with their steady growth and commitment to rewarding shareholders. The company recently declared an interim dividend for the six months ending on June 30, 2024, which will be payable on November 20, 2024. Despite positive news, the stock price took a hit as CSPC PHARMA (01093.HK) collapsed by approximately 9%, reaching a new low in 5.5 years. Analysts at CCBI trimmed their target price to $8 but maintained an outperform rating. Citi also adjusted their target price to $10 after the company’s interim results missed expectations. However, CSPC Pharmaceutical Group remains optimistic with an increase in interim underlying profit by 1.7% year over year and approval for a share buyback of up to $1 billion. Interim net profit saw a rise of 1.8%, with an interim dividend of $0.16 cents per share.

CSPC Pharmaceutical Group on Smartkarma

Analysts on Smartkarma, such as Tina Banerjee, are bullish on CSPC Pharmaceutical Group (1093 HK) as the company reported steady growth in finished drugs in 2023. New products like Mingfule, Yilouda, and Anfulike have driven sales ramp-up, with plans to launch 50 innovative drugs in the next 5 years. The company’s shares are trading at a low P/E of 11.3x, the lowest in the last five years, making them cheaper than peers. Additionally, CSPC Pharmaceutical offers an attractive dividend yield of over 4%.

A look at CSPC Pharmaceutical Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, CSPC Pharmaceutical Group has a generally positive long-term outlook. The company scores well in areas such as dividend, growth, resilience, and momentum, indicating strong performance in these aspects. With a focus on manufacturing and selling pharmaceutical products, including vitamin C, antibiotics, and generic drugs, CSPC Pharmaceutical Group is also involved in the development of innovative drugs and antibiotics, showcasing a commitment to staying competitive in the industry.

Overall, CSPC Pharmaceutical Group‘s Smart Scores suggest a solid foundation for the company’s future growth and stability. While there may be room for improvement in certain areas such as value and momentum, the high scores in dividend, growth, and resilience bode well for the company’s continued success in the pharmaceutical market. Investors and stakeholders may find CSPC Pharmaceutical Group to be a promising choice for long-term investment opportunities based on its strong performance across key factors.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma